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Background: The Extended Forsteo Observational Study (ExFOS) is a multinational, non-interventional, prospective,
observational study that aims to provide real-life data on patients with osteoporosis treated with teriparatide for
up to 24 months. It includes the new indications of osteoporosis in men and glucocorticoid-induced osteoporosis
(GIOP). We describe the Greek subpopulation enrolled in this study and compare it with a similar cohort from the
previous European Forsteo Observational Study (EFOS).
Methods: Baseline data were collected from the Greek cohort of ExFOS. Data included demographic characteristics,
medical and osteoporosis history, disease status, prior use of medications, back pain and quality of life.
Results: Baseline data for 439 patients, enrolled at 31 sites, indicated the majority of patients were females (92.3 %),
elderly [mean (standard deviation; SD) age 70.1 (9.8) years] and slightly overweight [mean (SD) body mass index
26.7 (4.3) kg/m2], with very low bone mineral density (mean T-score <−3 in lumbar spine or total hip) and at least
one previous fracture (55.1 % of patients). Of the 439 patients, 19.8 % were osteoporosis treatment naïve, 88.4 %
had experienced back pain during the previous 12 months, 68.1 % had experienced back pain at least fairly often
during the previous month and 50.9 % reported moderate to severe limitation of activities due to back pain, with a
mean (SD) of 4.2 (7.7) days spent in bed because of back pain during the previous month. Most baseline characteristics
were numerically similar between the female ExFOS and EFOS cohorts; however, the rate of enrolment was faster in
ExFOS (by approximately 45 %) and a history of fracture was recorded in 53.8 % of female patients in ExFOS versus
74.5 % in EFOS.
Conclusions: Greek patients prescribed teriparatide in ExFOS had severe osteoporosis with a high risk of fractures and
back pain. Female patients shared similarities with EFOS counterparts, reflecting a constant prescribing profile for use of
teriparatide, although a noticeable difference in fracture history between the two study cohorts may indicate a change
towards prescribing in less severely affected patients. The economic crisis in Greece did not appear to affect patient
enrolment. Data are interpreted in the context of an observational setting.
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Teriparatide is a well-established anabolic treatment
for osteoporosis [1, 2]. Numerous studies have provided
evidence of its efficacy in terms of bone density improve-
ment and reductions in the risk of fracture [3–10]. Among
these, the European Forsteo Observational Study (EFOS)
has recorded the benefits of teriparatide use in real life, in
reducing the risk of fracture, alleviating back pain and
improving quality of life, when used for up to 18 consecu-
tive months by postmenopausal women with osteoporosis
[4, 5, 11]. Greece was one of the eight European
countries that participated in this study, enrolling 302
(18.4 %) of the 1645 post-menopausal women with
severe osteoporosis and considerable health-related
problems [12, 13]. Teriparatide treatment was associated
with significant improvements in Greek patients’ quality
of life and back pain, together with reduced fracture rates
and a high rate of treatment compliance [11].
Randomised controlled trials are the gold standard for
treatment evaluation, yet they often under-represent the
patient population in real life. Observational studies can
provide valuable information that complements results
obtained from randomised controlled trials and extends
knowledge, identifying clinically important differences
between therapeutic options [14]. In this context, results
from EFOS have made an important contribution to the
accumulating knowledge concerning teriparatide. Since
EFOS, teriparatide has been licensed for the treatment
of osteoporosis in men at increased risk of fracture, for
the treatment of glucocorticoid-induced osteoporosis
(GIOP) in men and women at increased risk of fractures,
and the potential duration of teriparatide therapy has
been extended to up to 24 months in the European
Union [15].
The economic crisis in Greece has had a deteriorating
impact on health care provision in the country [16, 17].
While there are data to support the cost-effectiveness of
teriparatide [18], health-economic studies have not been
conducted in Greece. Patients are eligible for treatment
with teriparatide only after case review by special health
committees and once all criteria for reimbursement have
been fulfilled. In this economic arena, at least 5 years
after EFOS, Greece participated in the Extended Forsteo
Observational Study (ExFOS) [19]. This is a multinational,
non-interventional, prospective, observational study to
evaluate fracture outcomes, back pain, compliance and
health-related quality of life in patients with osteoporosis
treated with teriparatide, incorporating the drug’s additional
indications and extended treatment duration, as described
earlier. Analysis of the background characteristics of the
Greek cohort from ExFOS, and comparison of the findings
with those of the Greek cohort from EFOS, could
give an important and intriguing insight into changes
in the prescribing habits of Greek health care providers asa result of changes in the Social Security System criteria for
reimbursement on prescription of teriparatide occurring
amidst an economic crisis. As the Greek EFOS patients
were enrolled between July 2004 and September 2005, and
the Greek ExFOS patients were enrolled between February
2011 and May 2012, we additionally sought to answer the
following questions: a) What may have changed during the
intervening period of 5 to 6 years of teriparatide use in a
national population with relative homogeneity? b) How
have health economics affected prescribing of teriparatide
in a country with severe financial problems? c) How have
the new indications for teriparatide affected treatment
choices for health care practitioners? This report describes
the baseline profile of Greek patients treated with teripara-
tide in ExFOS, provides details by gender and juxtaposes
the characteristics of female Greek patients enrolled in
ExFOS with those enrolled in EFOS.
Methods
The study was conducted in compliance with the
Declaration of Helsinki and local approval was provided
by the Hellenic National Organization for Medicines
(NOM) [reference number: NIS-22/01-03/10, 31 January
2011]. All patients provided written informed consent
before entering the study. Full details of the design
and data acquisition in ExFOS have been published
elsewhere [19]. In summary, baseline assessments included
recording patient demographic characteristics, lifestyle and
risk factors for osteoporosis and falls, prior and current
osteoporosis therapies, and any accompanying diseases. In
addition, the start date and reimbursement details for
teriparatide treatment were noted and information on
bone mineral density (BMD) was collected together with
the history, number and location of any osteoporotic
fractures before the start of treatment. Back pain,
self-assessed by patients, was recorded. Use of anal-
gesia for back pain in the past month and the severity
of pain during the last month were also recorded.
Health-related quality of life was assessed using the
EuroQol-5 Dimension (EQ-5D) instrument and the
related visual analogue scale (EQ-VAS).
Data management and analyses were conducted accord-
ing to a pre-specified (common for all participating
countries) statistical analytical plan that provided descrip-
tive summary statistics only [mean and standard deviation
(SD) for continuous data; number and percentages for
categorical data]. These were used to describe the total
study population of 1607 patients with osteoporosis at
baseline [19].
Regarding bone mineral density, given the fact that
there was no specific request per protocol, other than
the investigators’ clinical practice, an analysis of obtained
measurements per measurement site has been facilitated.
T-scores were reported in standard deviation units relative
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When patients had several measurements at one location,
the last nonmissing value before baseline was used; if
several measurements at the same location and date
were available, then the lowest nonmissing value was
used. Since in Greece only one location measurement
is reimbursed, it is probable that results of different
locations may not apply to same patients (i.e. lumbar
spine measurements may have been recorded from
different patients than femoral neck measurements). For
this reason BMD is described by the measurement result
and the number (N) of measurements captured.
An additional post-hoc descriptive statistical analysis was
performed using the Greek cohort to evaluate results by
gender, taking into account the small size of the male sub-
population in ExFOS, and to descriptively compare results
from the postmenopausal female patients in ExFOS with
those from the 302 postmenopausal women in the EFOS
Greek cohort included in the analyses of Karras et al. [12].
Results
Patients
A total of 31 investigative sites in Greece enrolled 439
patients with osteoporosis (92.3 % female) between 16
February 2011 and 24 May 2012, an enrolment period of
15 months. The mean enrolment rate was 0.95 patients/
site/month (calculated by dividing the total patient number
enrolled by the total number of investigational sites and
the total enrolment period). Baseline characteristics of
these patients are shown in Table 1, together with a gender
sub-analysis. For comparison, baseline characteristics of
the Greek cohort from EFOS are also included [12].
Greek patients enrolled in ExFOS were generally elderly
[mean (SD) age 70.1 (9.8) years; 36.4 % aged 75 years or
older] and slightly overweight with a mean (SD) body
mass index of 26.7 (4.3) kg/m2. The majority of patients
(92.3 %) were women, who had been post-menopausal for
a mean (SD) of 22.1 (10.3) years and had experienced a
mean (SD) of 34.6 (5.6) fertile years; 5.5 % reported early
menopause (Table 1). Of the 405 women, 92.1 % had given
birth to least one child and 30.6 % were multiparous with
three or more children. Although 73.8 % of patients
reported no concurrent disease, existing predisposing risk
factors for fracture were fairly common: 18.1 % reported a
history of maternal hip fracture, 37.1 % had experienced a
fall in the last year and 37.9 % had sight problems. In
addition, 49.2 % of all patients took no exercise, 12.1 %
were current smokers (33.3 % of men, 10.4 % of women)
and 74.8 % had never smoked. Muscle weakness, recorded
as the need to use arms when standing up from a chair,
was reported in 41.3 % of patients; however, only 1.6 % of
patients had been immobilised for > 12 months. In
addition, 69.5 % of all patients used at least one medication
associated with a risk of osteoporosis or falls; specifically,current glucocorticoid use was reported by 8.9 % of
patients, more commonly in men (17.6 %) than women
(8.1 %). Other drugs in this category (medication related to
osteoporosis and falls) included antihypertensives (47.6 %),
thyroid hormones (21.2 %), antidepressants (12.3 %),
antiarrythmics (9.1 %) anticoagulants or heparin (7.1 %),
benzodiazepines (5.7 %), antidiabetic drugs (4.8 %) and
anticonvulsants (2.1 %).
Bone mineral density and fracture history
Table 2 depicts the distribution of BMD measurements
per location. Recent (within 6 months prior to study
entry) mean (SD, N) BMD T-scores were −3.4 (0.7, 280)
for the lumbar spine and −3.2 (0.5, 82) to −3 (0.5, 37)
for the total hip and −2.8 (1.2, 45) to −3.0 (0.5, 20) for
femoral neck (left and right leg respectively). At least
one osteoporotic fracture had already been diagnosed in
55.1 % of patients at baseline (70.2 % of these patients
had vertebral fractures and 44.2 % had non-vertebral
fractures), and 21.6 % of patients had two or more previous
osteoporotic fractures. The mean (SD) number of previous
fractures for patients with at least one fracture was 1.7 (1.1)
[vertebral fractures 1.6 (1.0), non-vertebral fractures 1.3
(0.7)]. The most recent fracture had occurred a mean (SD)
of 2.6 (5.1) years before entry into the study. Importantly, a
fifth of male respondents (20.8 %) suffered a hip fracture,
roughly triple the proportion of female participants (6.9 %).
Figure 1 shows the location of fractures for patients with a
history of osteoporosis-related fractures.
Treatment for osteoporosis
Overall, 19.8 % of Greek patients enrolled in ExFOS
were osteoporosis treatment naïve at baseline; more women
than men had received prior osteoporosis medication
(82.2 % of women versus 55.9 % of men). Of the 352
patients treated with osteoporosis medication before
enrolment, 73.6 % had used bisphosphonates and 29.0 %
calcitonin, while only 10.5 % of patients had used stron-
tium and 6.3 % raloxifene. Prior calcium and vitamin D
supplementation was used by 91.5 % and 90.6 % of patients
receiving osteoporosis treatment, respectively.
Back pain
The majority of patients (88.4 %) had experienced back
pain during the previous 12 months. Of the 376 patients
who had back pain in the previous month, 23.7 % had
experienced back pain fairly often and 44.4 % had
experienced back pain every day or almost every day, the
pain being moderate or severe in 80.9 % of patients.
Moderate or severe limitation of activities in the past
month due to back pain was reported by 50.9 % of
participants, with a mean (SD) of 4.2 (7.7) days spent in
bed because of back pain. Use of an analgesic medication
for back pain in the month before baseline was reported
Table 1 Descriptive baseline characteristics of Greek patients enrolled in ExFOS and EFOS





Enrolment period (dates of first and last patient enrolment) 16 Feb 2011 – 24 May 2012 // // 05 Jul 2004 – 30 Sep 2005
Enrolment rate (patients/site/month) 0.95 // // 0.65
Number of patients (% women) 439 (92.3) 34 405 302 (100)
Mean (SD) age (years) 70.1 (9.8) 71.5 (10.3) 70.0 (9.8) 70.0 (8.5)
Mean (SD) BMI (kg/m2) 26.7 (4.3) 26.4 (4.6) 26.7 (4.3) 26.3 (4.0)
Menstrual history
Mean (SD) time since menopause (years) - - 22.1 (10.3) 24.4 (9.0)
Mean (SD) fertile period (years) - - 34.6 (5.6) 32.4 (5.9)
Early menopause before age 40 years (% patients) - - 5.5 9.3
Fracture risk factors (% patients)
Current smokers 12.1 33.3 10.4 12.6
No exercise 49.2 61.8 48.1 71.5
Hip fracture in biological mother 18.1 14.8 18.4 16.6
One or more falls in the preceding year 37.1 50.0 36.0 40.7
Assist standing using arms 41.3 58.8 39.8 92.1
Bone health
Mean (SD) DXA BMD spine −3.4 (0.7) −3.3 (1.3) −3.4 (0.7) −3.4 (0.7)
Mean (SD) DXA BMD total hip (higher N included) −3.2 (0.5) −3.4 (0.6) −3.2 (0.5) −2.8 (1.1)
Mean (SD) DXA BMD femoral neck (higher N included) −2.8 (1.2 −3.0 (0.4) −2.8 (1.2) −3.1 (0.8)
Fracture history (% patients) 55.1 70.6 53.8 74.5a
Mean (SD) fracture number (for patients with at least one fracture) 1.7 (1.1) 2.0 (1.9) 1.7 (1.0) 1.8 (1.4)
Patients with vertebral fractures (% patients) 38.7 50 37.8 59.6b
Patients with vertebral fractures (% of patients with fractures) 70.2 70.8 70.2 85.9
Patients with hip fractures (% of patients with fractures) 8.3 20.8 6.9 2.7
Prior treatments (% patients)
Prior anti-osteoporotic treatments 80.2 55.9 82.2 83.1
Calcitonin 23.2c 5.9 24.7 64.6
Bisphosphonates 59.0c 32.4 61.2 36.1
Prior glucocorticoid use 8.9c 17.6 8.1 14.6
Back pain and quality of life variables
Back pain in the previous year (% patients) 88.4 76.5 89.4 97.4
Moderate to severe pain in the month before enrolment (% patients) 80.9 88.0 80.4 85.3
Mean (SD) EQ-5D VAS (cm) 57.0 (21.7) 56.9 (20.7) 57.0 (21.8) 54.2 (24.9)
aIn EFOS, 15.9 % of patients did not have a fracture history and data were missing for 9.6 % of patients
In ExFOS, 44.9 % of patients did not have a fracture history
bData on file
cPercentage of all patients enrolled
BMD, bone mineral density BMI, body mass index; DXA, dual-energy X-ray absorptiometry; EFOS, European Forsteo Observational Study; ExFOS, Extended Forsteo
Observational Study; SD, standard deviation, VAS, visual analogue scale
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sics were paracetamol (86.8 % of those taking analgesic
medication) and non-steroidal anti-inflammatory drugs/
aspirin (45.7 %), with these two types of analgesic being
used daily by 50.6 % and 55.0 % of patients reporting their
use, respectively. The baseline mean (SD) back pain VAS
score was 52.4 (29.5).Quality of life
The baseline mean (SD) EQ-VAS score was 57.0
(21.7). Figure 2 shows the frequency of perceived
problems in each of the five domains of the EQ-5D.
The highest frequency of severe problems was ob-
served in the pain/discomfort and anxiety/depression
domains.
Table 2 Bone mineral density per measurement location, reported as percentage of measurements per location (Number of
measurements)
Measured site (percentage per location and
number of patients, p (N)
BMD≤ −3.5 −3.5 < BMD≤ −2.5 −2.5 < BMD≤ −1 BMD > −1 Total
Lumbar spine 37.9 % (106) 55.4 % (155) 6.4 % (18) 0.4 % (1) 100 % (279)
Total Hip (left) 23.2 % (19) 70.7 % (58) 6.1 % (5) 0 % (0) 100 % (82)
Total Hip (right) 13.5 % (5) 73.0 % (27) 13.5 % (5) 0 % (0) 100 % (37)
Femoral Neck (left) 17.8 % (8) 64.4 % (29) 13.3 % (6) 4.4 % (2) 100 % (45)
Femoral Neck (right) 15.0 % (3) 80.0 % (16) 5.0 % (1) 0 % (0) 100 % (20)
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ExFOS enrolled patients reported, via questionnaire,
whether the treatment would be reimbursed by public
or private security. Reimbursement of teriparatide in
Greece was almost exclusively covered by public health
insurance. For this reason all patients went through a
state committee that ensured treatment criteria were
met in each and every case. During the 15 months of
enrolment, which coincided with changes in the national
reimbursement procedures, monthly enrolment varied
from 11 to 45 patients per month. There was no evidence
of enrolment variability associated with socioeconomic
milestones during the study.
Juxtaposing description ExFOS and EFOS cohorts at
baseline
When descriptively analysed, the EFOS and ExFOS
female Greek cohorts appear to have similar age,
somatometric measurements and bone density mea-
surements (Table 1). Both cohorts exhibited severeFig. 1 Location of fractures for Greek patients with a history of osteoporososteoporosis with a high risk for new fractures, and
experienced relatively frequent and severe back pain
and diminished quality of life. Women in the ExFOS
cohort seemed to be active (with higher exercise
rates) and less frequently needed to use their arms
when standing up from a chair. Noticeably, a lower
percentage of women in ExFOS reported a history of
fracture compared with women in the EFOS cohort.
A similar percentage of women in both studies had
received no previous osteoporosis treatment (17–18 %).
Among the women in the ExFOS cohort, prior use of
calcitonin was lower and prior use of bisphosphonates
higher, than that seen in the EFOS cohort. Fewer
women in ExFOS had a history of glucocorticoid use
than in EFOS. Figure 3 depicts fracture prevalence in
EFOS and ExFOS female participants.
Discussion
In the current analysis, we have attempted to address
questions about prescribing habits for teriparatide inis-related fractures (N = 242)
Fig. 2 Patient quality of life at baseline according to the five EQ-5D domains. N = 426 for each domain except Usual Activity where N = 425
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the baseline characteristics of the Greek ExFOS cohort.
Greece enrolled the highest number of participants in
ExFOS among the eight participating countries [19].
From EFOS to ExFOS
Baseline findings of both observational studies suggested
that Greek patients suitable for teriparatide treatment
tended to be elderly, have severe osteoporosis and be
at high risk of new fractures. They also had relatively
frequent and severe back pain, which can affect mobility
and consequently quality of life [20–22]. A descriptive
comparison between the two studies (Table 1) suggests
that women initiating treatment with teriparatide
more recently (ExFOS) were relatively healthier, more
active, exercised more frequently, could rise from a
chair more easily and had fewer previous fractures
than their counterparts from EFOS.
In Greece, teriparatide treatment is usually only initiated
following prior treatment with anti-osteoporotic medica-
tions. While the use of prior osteoporosis medication was
high in the total ExFOS cohort, a considerable proportion
of patients (19.8 %) were treatment naïve, in common
with the EFOS cohort (16.9 %). Since experience with all
osteoporosis medications has increased in the period
between these two studies and the insurance needs
for teriparatide reimbursement include failure of prior
osteoporosis treatments, we can only speculate that
the treatment naïve patients have been first diagnosed
with osteoporosis after a severe event, such as clinical
fracture. Our observations indicate there has been a
decrease in calcitonin use in recent years, which mayreflect concerns of Greek health care practitioners
concerning the benefits and risks of calcitonin-containing
medicines. These concerns would have been manifest
before the final recommendation of the European
Medicines Agency (EMA) that calcitonin use should be
limited for the treatment of osteoporosis (this recommen-
dation was made in July 2012, 2 months after enrolment
into ExFOS was completed, and stated that calcitonin-
containing medicines should only be used for short-term
treatment because of evidence that long-term use is
associated with an increased risk of cancer, and further
that they should no longer be prescribed as nasal sprays
for the treatment of osteoporosis) [23].
The study enrolment rate appeared to increase by about
45 % in ExFOS compared to EFOS. This may be explained
by the increased familiarity of health care practitioners
with teriparatide, and its benefits and risks, and greater
awareness of observational studies and the benefits of
enrolment. Indeed, many sites were common in both
Greek studies, which ameliorates a possible bias due to
differing investigators’ perceptions in each study.
The proportions of patients enrolled without a his-
tory of fracture increased considerably between the
two studies (in EFOS 15.9 % had confirmed no frac-
ture history and 9.6 % did not provide data versus
46.2 % with no fracture history in the female Greek
ExFOS subgroup); this discrepancy may be explained in
part by changes to reimbursement criteria. A criterion for
teriparatide use—only after sustained fracture—was in
place during EFOS, but was removed after May 2007.
Thus, in ExFOS, committees were able to approve treat-
ment with teriparatide regardless of fracture history.
Fig. 3 Short title: Location of previous fractures for Greek ExFOS and EFOS participants. Detailed legend: Location of previous fractures in the
Greek ExFOS cohort (by gender) and Greek EFOS cohort for (a) all patients in the cohort and (b) for patients with at least one previous fracture
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prescription habits
The Greek health system is complex and based on interplay
between a national system financed by the state, and
medical expenses financed by social insurance organisa-
tions for insured patients. Funding for health services and
products comes primarily from the state budget and social
insurance funds [24].
Teriparatide was almost exclusively reimbursed via public
insurance institutes. Public reimbursement criteria as well
as reimbursement coverage rates have been amended in
many occasions during the ExFOS enrolment period.
Since the economic crisis caused a deterioration of
health care [16, 17] and considering the problems faced re-
garding drug provision by private pharmacies, particularlyfor teriparatide we were anticipating enrolment delays,
especially at milestones of important health care changes.
Nevertheless, these factors did not negatively affect enrol-
ment into ExFOS, since the enrolment rate pattern per
month was similar to that of other observational studies
performed before the economic crisis.
Results from ExFOS show that, at present, teriparatide-
treated patients are largely elderly patients. As this
segment of the population usually comprises insured
pensioners, and since teriparatide is, currently, 100 % re-
imbursed after being approved by a specialized committee,
few patients are currently affected financially. In addition,
most patients suitable for teriparatide treatment still visit
their healthcare practitioner. In the future, this picture
could change. Indeed a growing portion of the Greek
Aloumanis et al. BMC Musculoskeletal Disorders  (2015) 16:136 Page 8 of 10population no longer seek preventive care. Whether this
will affect consulting patterns during ExFOS and the
long-term outcomes of the study remains to be seen.
Impact of EU license changes on prescription habits
The most important change in the EU label of teriparatide,
the extension of teriparatide treatment for up to 24 months,
has been incorporated into the ExFOS protocol. This
longer duration of therapy has been associated with an
increase in non-vertebral fracture protection and a reduc-
tion in back pain [25]. Observational studies, such as
DANCE (Direct Assessment of Non-vertebral Fractures in
the Community Experience), have shown that the reduction
in the risk of non-vertebral fractures during 24 months of
teriparatide treatment in men and women with osteopor-
osis stabilises during the last 6-month treatment period
[26]. Furthermore, improvements in the severity of back
pain and quality of life have also been recorded after
24 months of teriparatide treatment in postmenopausal
women with osteoporosis [27]. ExFOS may provide data on
the effect of this extended period of teriparatide treatment
on the risk of fracture and the reduction in back pain.
Following the new indication for teriparatide of male
osteoporosis, 34 Greek men (7.3 %) were enrolled in
ExFOS; however, women still out-numbered men by more
than 10-fold in the study cohort. This is accordance with
Greek epidemiological studies, showing that the preva-
lence of osteoporosis is more than 10-fold higher in Greek
women than in Greek men [28]. The number of treated
Greek men in ExFOS could be perceived as lower than
expected. However, despite causing significant morbidity
and mortality [29], male osteoporosis is still under-
diagnosed, even in those with vertebral deformities [30].
Male patients treated with teriparatide were also in the
minority in other observational studies, which included a
similar percentage of males to that in our study
(ISSO study: 9.5 % [31], DANCE study: 9.6 % [32],
Yu et al.: 9 % [33]). As reported by Wong et al., in the
DANCE study, patient gender may influence a physician’s
decision to initiate teriparatide therapy, despite a similar
proportion of men and women having prior fragility frac-
tures at baseline and comorbid conditions that increase
the risk of fracture [32]. Frailty, low body mass index
and inadequate response or intolerance to previous
osteoporosis therapy were reasons for physicians prescrib-
ing teriparatide more often in women than in men,
whereas chronic glucocorticoid therapy was given as a rea-
son for initiating teriparatide more often in men than
women [32]. Likewise, in our study population, twice as
many men as women had a history of glucocorticoid
use. These results suggest a preference for prescribing
teriparatide in females, regardless of the baseline risk
of fracture. However, it is also possible that men were
less likely than women to consent to participate in anobservational study of a widely perceived ‘female’
health problem, even though men are generally more
likely than women to enrol in clinical trials [34].
In our cohort, only about half of the enrolled men had
received prior osteoporosis treatment. It is possible that
our study included patients (especially men) who sustained
fractures in the past but were never treated for osteopor-
osis, since data support low osteoporosis treatment rates in
patients with a prevalent fracture [35]. In addition, the
observation that men had experienced almost triple the
number of hip fractures experienced by women, may pro-
vide further support for the finding that, in this study, teri-
paratide was used in men with more severe osteoporosis
and newly diagnosed osteoporosis already complicated by
fractures. We should note, however, that the low number
(n = 34) of the males in the study population could be chal-
lenging in some respects and is a major limitation of the
current per gender subanalysis.
Data on the use of teriparatide in GIOP are not available
for our population from ExFOS. It is estimated that 2.5 %
of the elderly population aged 70–79 years in Britain are
prescribed oral glucocorticoid therapy [36]. Our popula-
tion has the same age range, yet past glucocorticoid use
was reported in a higher percentage of patients (8.9 %).
Interestingly, oral glucocorticoid use was reported in an
even higher percentage of patients from the EFOS Greek
cohort (Table 1). Nevertheless, we consider it unlikely that
GIOP was an important factor for teriparatide treatment,
at least in patients enrolled in the current ExFOS study.
The lack of specific recommendations for teriparatide
treatment in GIOP due to cost, the absence of long-term
data (due to the restricted duration of administration),
and the actual or perceived inconvenience of a daily injec-
tion for 24 months [36] may explain the apparent decrease
in the numbers of these patients in a study (ExFOS) in
which a specific relevant indication has been incorporated.
However, we know from the full EFOS cohort [37] that
for the 18.6 % of women who were glucocorticoid users at
any time during the study and who were treated with teri-
paratide for up to 18 months, analysis of fracture data in
6-month segments revealed that the adjusted odds of frac-
ture were significantly decreased during the last year of
follow-up (i.e., during the two 6-month periods covering
24–36 months after teriparatide was discontinued) com-
pared with the first 6 months of teriparatide treatment: an
81 % decrease in the 24 to <30-month period (p < 0.05),
and an 89 % decrease in the 30 to < 36-month period
(p < 0.05). In addition, the glucocorticoid user group in
EFOS demonstrated significant reductions in back pain and
improvements in quality of life during teriparatide treat-
ment that were maintained after the drug was discontinued
[37]. It will be interesting to see the impact of a longer
duration of teriparatide treatment (i.e. 24 months) on this
specific population in the ExFOS cohort.
Aloumanis et al. BMC Musculoskeletal Disorders  (2015) 16:136 Page 9 of 10Regarding back pain, which is a very common symptom
in the elderly in the absence of osteoporosis, its evolution
during treatment is of great interest to us, considering the
favourable effects shown in EFOS [4, 5, 38] as well as
other studies [39], in contrast to the lack of differences in
back pain-related endpoints in a head-tohead trial
with risendronate [40]. Since these patients seem to
have lower rates of fractures at treatment initiation, it
will be of interest to observe self-reported back pain
validation as a consequence of teriparatide treatment.Conclusions
In conclusion, Greek patients prescribed teriparatide in
ExFOS had severe osteoporosis with an increased risk of
fractures and back pain. Baseline data from the female
Greek cohorts of ExFOS and EFOS suggest that the two
study populations are relatively homogenous and, as a
result, can provide interesting insights regarding the use
of teriparatide for the treatment of osteoporosis in
the past (EFOS) and present (ExFOS). A constant
prescribing profile for teriparatide has been enriched
by a noticeable difference in fracture history between the
two study cohorts, which follows National reimbursement
criteria and may indicate a change towards prescribing of
teriparatide for less severely affected patients. The eco-
nomic crisis in Greece did not seem to affect patient
enrolment into ExFOS. Data are interpreted in the context
of an observational setting.
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